Innovative Technology Bioprocess Controller Streamlines Process Scale-Up
Eppendorf’s new Bioflo 720 is a bioprocess control station which can be used for process scale-up from R&D labs to pilot and manufacturing facilities. The solution’s innovative software saves time, increases efficiency and reproducibility.
Streamlining the transfer of an upstream bioprocess from research to production scale is critical for reducing biologics development costs and time to market. Eppendorf introduces the Bioflo 720, a bioprocess control station for applications at pilot/production scale using single-use bioreactors. With it, the company now offers one of the most scalable and comprehensive single-use portfolios on the market, for seamless process scale-up from R&D labs to pilot and manufacturing facilities, states the firm.
The new bioprocess control station is compatible with Thermo Fisher Scientific Hyperforma 5:1 single-use bioreactors. In combination with the firm’s Bioblu Single-Use Vessels for small and bench scale bioprocesses, the company offers pharmaceutical and biotech companies the benefit of an integrated scalable portfolio, including manufacturing solutions for regulated environments, adds the firm.
According to the company, innovative software features help saving time, increase efficiency and reproducibility by automating repetitive process steps:
• Auto Inflate automatically controls the inflation process for flexible single-use bioreactors
• Auto Calibrate automatically calibrates all attached DO sensors at once
• Scale Up Assist calculates scaling-relevant parameters based on constant tip speed or power input per volume
For added flexibility, configurable gas flow control, sensor connections, pump options, and software settings enable the system to meet a variety of process needs.
With a narrow footprint of only 81 x 87 cm (32” x 34”), the bioprocess control station minimizes space utilization. Designed as a mobile controller it can be quickly deployed into any bioprocess project in research or regulated environments, concludes the firm.